Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?

Transl Androl Urol. 2024 Apr 30;13(4):647-649. doi: 10.21037/tau-23-569. Epub 2024 Apr 18.

Authors

Benjamin Lichtbroun¹, Saum Ghodoussipour¹, Vignesh T Packiam¹

Affiliation

¹ Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.

No abstract available

Keywords: Non-muscle-invasive bladder cancer (NMIBC); ablative therapy; mitomycin.

Publication types

Editorial
Comment